Аңдатпа
e17034 Background: Randomized trials have showed a good result of concurrent chemoradiotherapy in advanced SCC of the head and neck. But there are only few trials which evaluates separately the different sites of the head and neck. The aim was to evaluate the toxicity and efficacy of concurrent intra-arterial chemotherapy plus radiotherapy with altered fractionation in SCC of the oral cavity. Methods: 43 patients with previously untreated oral cavity SCC (T3–4N0–2M0) received concurrent chemoradiotherapy by followed scheme: first day intra-arterial chemotherapy: docetaxel - 80 mg/m2, cysplatin - 100 mg/m2, from second to 21st day RT (28 Gy by 4 Gy - 3 times week), 22nd day second course of intra-arterial chemotherapy and after RT (total dose- 60 Gy by 2 Gy 5 times week, total equivalent to 70Gy by conventional fractionation), depending on the results salvage surgery if necessary. Results: The clinical effects were pCR in 34 (79.1%) patients, pPR in 9 (20.9%) patients. The following main toxicities of chemoradiotherapy were observed: only 2 cases of grade 3 neutropenia, Non-hemathologic toxicity: 74.4% (32 patients) grade 3 mucosal events. All patients have totally completed the treatment. The 3-year overall survival rate were 83.7%, and 3-year disease free survival were 76.7%. Conclusions: This regimen of concurrent chemoradiotherapy where radiotherapy is used by altered fractionation is feasible, safe and well tolerated. No significant financial relationships to disclose.